E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To investigate the effects on cognitive function of once daily dosing for 24 weeks with SB-742457 versus placebo. • To investigate the effects on global functioning of once daily dosing for 24 weeks with SB-742457 versus placebo.
|
|
E.2.2 | Secondary objectives of the trial |
• To investigate the effects on cognitive function of SB-742457 or placebo after 8 and 12 weeks of treatment • To investigate the effects on global functioning of SB-742457 or placebo after 8 and 12 weeks of treatment • To investigate the effects on behaviour of SB-742457 or placebo after 8, 12 and 24 weeks of treatment • To investigate the effects on activities of daily living of SB-742457 or placebo after 8, 12 and 24 weeks of treatment • To seek post-hoc correlation of any effects of SB-742457 with apolipoprotein E (ApoE) genotype and possibly other pharmacogenetic markers. • To investigate the safety and tolerability of SB-742457 or placebo in subjects with mild to moderate AD. • To evaluate the PK of SB-742457 in subjects with mild to moderate AD. • To evaluate the relationship, if any, between SB-742457 exposure and cognitive function and global functioning. • To evaluate patient and caregiver perception of benefit of treatment with SB-742457 for 24 weeks.
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Male or female subject with a clinical diagnosis of probable Alzheimer's disease in accordance with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria and National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria. 2. Subject has mild to moderate Alzheimer's disease with MMSE score 12-24 inclusive at the screening visit and 12-26 inclusive at the end of the placebo run-in period . 3. Fifty to 85 years of age inclusive. 4. Female subjects must be post-menopausal (i.e. >24 weeks without menstrual period) or surgically sterile. Female subjects who have been post-menopausal for < 2 years must undertake pregnancy testing (βhCG) at Visit 1, which must be negative. 5. Subject has the ability to comply with procedures for cognitive and other testing. 6. Subject lives with (or has substantial periods of contact with) a permanent caregiver who is willing to attend all visits, oversee the subject's compliance with protocol-specified procedures and study medication, and report on subject's status. (Subjects living in a nursing home are not eligible.) 7. Subject has provided full written informed consent prior to the performance of any protocol-specified procedure; or if unable to provide informed consent due to cognitive status, full written informed consent on behalf of the subject has been provided by a legally acceptable representative. 8. Caregiver has provided full written informed consent on his/her own behalf prior to the performance of any protocol-specified procedure.
|
|
E.4 | Principal exclusion criteria |
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
Other Causes for Dementia 1. Diagnosis of possible, probable or definite vascular dementia in accordance with National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche l’Enseignement en Neurosciences (NINDS-AIREN) criteria. 2. History and/or evidence (CT or MRI scan performed within the past 12 months or at Screening) of any other central nervous system (CNS) disorder that could be interpreted as a cause of dementia: e.g. cerebrovascular disease, structural or developmental abnormality, epilepsy, infectious, degenerative or inflammatory/demyelinating CNS conditions. 3. Focal findings on the neurological exam (excluding changes attributable to peripheral injury). 4. Untreated abnormal result of any of the following tests: vitamin B12, syphilis serology, thyroid stimulating hormone (TSH), where this is thought to be the cause of, or to contribute to the severity of, the subject’s dementia.
Confounding Medical Conditions 5. History of significant psychiatric illness such as schizophrenia or bipolar affective disorder that in the opinion of the Investigator would interfere with participation in the study, or current depression (score on Centre for Epidemiological Studies - Depression Scale (CES-D) >18). 6. History of known or suspected seizures, including febrile seizures, unexplained recent loss of consciousness or history of significant head trauma with loss of consciousness. 7. History or presence of significant cardiovascular, gastro-intestinal, hepatic, or renal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, or any other clinically relevant abnormality, medical or psychiatric condition, which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study. 8. History of alcohol or other substance abuse, according to the DSM-IV criteria. 9. Treatment with any Concomitant Medications as specified in Section 9.2 10. Systolic blood pressure >165 mmHg or diastolic blood pressure >95 mmHg. 11. Postural hypotension (fall in systolic blood pressure of >30mmHg or fall in diastolic blood pressure of >20mmHg on standing compared to supine). 12. Abnormal liver/kidney function tests (more than 1.5 times normal). 13. Calculated creatinine clearance < 50ml/min (Cockroft-Gault formula) or clinically relevant finding (more than 1+ protein or blood) on urinalysis (including microscopy). Other 14. Subject is unable (with assistance, if appropriate) to take study medication as prescribed throughout the study, has a history of non-compliance with prescribed medication, or is at risk of non-compliance with study medication or procedures. 15. Subject or caregiver is an immediate family member or employee of the participating Investigator, any of the participating site staff or GSK staff.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The co-primary endpoints to assess cognition and global functioning are:
1. Change from baseline to Week 24 in Alzheimer's Disease Assessment Scale cognitive (ADAS-cog) score (Appendix 5 of Protocol). 2. Change from baseline to Week 24 in Clinician's Interview-Based Impression of Change – plus (CIBIC+) score (Appendix 6 of Protocol).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
A phase IIa/b double-blind, randomised, placebo-controlled, linear trend design dose-ranging study |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject undergoing the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |